Skip to main content

Table 4 The side-effect of patients with aPAP during the GM-CSF treatment and follow up period

From: Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

  Treatment periods Follow up periods
No treatment group (n = 17) Treatment group (n = 19) P value No treatment group (n = 12) Treatment group (n = 16) P value
Leukocytosis 1/17 (5.9%) 1/19 (5.3%) 1.0a 1/12 (8.3%) 0/16 (0) 0.429a
Increase in aminotransferases 4/17 (23.5%) 11/19 (57.9%) 0.037 6/12 (50.0%) 4/16 (25.0%) 0.333b
Increase in bilirubin 6/17 (35.3%) 2/19 (10.5%) 0.167b 4/12 (33.3%) 0/16 (0) 0.051b
  1. a: Fisher X2 test; b: continuous correction X2 test